רשימת הודעות בפורום

לארשי םירירש תולחמ-י.ש.מ םורופ

תועדוה
(דומעה שארב תועיפומ םורופב תונורחאה תועדוהה)

תועדוהה לכ תא רוגס

תועדוהה לכ תא חתפ

(10:04 26/08/08) קחציו הליא ךוניח תודסומב תושיגנ

(10:23 25/08/08) ריירב ןרוא םיהדמ דוקיר עפומ תעגל קר

(14:12 20/08/08) קחציו הליא .S.M.A תלחמב עוצקמ ישנאל יעדמ סנכ

(14:21 20/08/08) קחציו הליא [ת"ל] איה סנכה לע עדימל הנוכנה תבותכה

(00:02 09/05/08) הרמכ השנמ 21/10/07 ב םסרופ-ןשודב תימתס היצטומלםייוסינב תוחלצומ תואצןת

(00:08 09/05/08) הרמכ השנמ 21/10/07 םסרופ-ןשודל ןוסקא גולידב םיינילק םייוסינ

(11:19 29/05/08) טדימשדלוג הויז הנעי והשימש השקבב - ןשוד אשונב תולאש

(13:23 29/05/08) ןממ ודוד [ת"ל] תולאש לע םכל תונעל ןכומ ןשוד הלוח 23 ןב ינא

(21:16 29/05/08) ל תלייא הוויזל

(02:56 10/07/08) ורקוזוק תינר הוויזל

(23:02 16/07/08) רמידרוג הנלסור הויזל

(12:16 06/07/08) הכלמ הסיל רמושה לת םוקיש וא ןילא ח''ב

(02:54 10/07/08) ורקוזוק תינר הסיל

(20:31 19/06/08) כהן מירי עזרה בתרגום מאמר לעברית SMA תיקון

Families of Spinal Muscular Atrophy and Paratek Pharmaceuticals Extend and Expand Drug Discovery Collaboration for Spinal Muscular Atrophy

LIBERTYVILLE, Ill., and BOSTON, June 17 /PRNewswire/-- Families of Spinal Muscular Atrophy (FSMA) and Paratek Pharmaceuticals, Inc. today announced they have extended and significantly expanded their joint research and development collaboration to develop a drug candidate for the treatment of Spinal Muscular Atrophy (SMA), the leading genetically inherited cause of death of children under the age of two years. The collaboration is focused on optimizing and advancing into the clinic a novel small molecule within Paratek's library derived from the tetracycline class of compounds.

The partners have agreed to extend their collaboration for a third year and to approximately triple the resources dedicated to the program, with both partners increasing their investment in the effort. The Krainer Laboratory at Cold Spring Harbor Laboratory and the Hastings Laboratory at Rosalind Franklin University of Medicine and Science are also key collaborators in the program.

Spinal Muscular Atrophy is an often-fatal genetic disorder resulting from the loss of both copies of the Survival Motor Neuron (SMN1) gene. This causes a chronic deficiency in the production of the SMN protein, which is essential to the proper functioning of the motor neurons in the spinal cord and to the control of muscles in the limbs, neck and chest.

"We are excited that the early, positive results of this collaborative program justify this new level of commitment," said Kenneth Hobby, Executive Director at FSMA. "Our drug discovery strategy is to invest funds to enable companies to begin early-stage programs for this orphan disease. As this and other programs progress to later stages, we are looking for funding to transition from non-profit to commercial sources."

This exciting announcement also coincides with the SMA community bringing its annual conference to Boston, where Paratek is headquartered. This is the largest conference in the world for families affected by SMA and also for the researchers and companies working to discover treatments and a cure for this devastating disease. Mayor Thomas M. Menino has proclaimed Saturday, June 21st as "SMA Awareness Day" for the City of Boston. Mr. Hobby stated, "FSMA is excited to be in Boston for our conference this year -- an important hub of the biotech industry in the U.S. During our conference, we hope to increase awareness about SMA to the Boston biotech community."

Jill Jarecki, Ph.D., FSMA's Research Director added, "The goal of this effort is to develop an SMA drug that safely and effectively restores the proper amount of SMN protein in the body by correcting the splicing of the SMN2 gene. Compounds generated by Paratek have been shown to accomplish this in a number of tissues in animal models of the disease."

Dr. Stuart B. Levy, M.D., Paratek's Vice Chairman, Chief Scientific Officer and co-founder, stated, "We are extremely pleased with the continuation and expansion of our collaboration with FSMA and equally excited about the progress of our SMA program. Developing a clinical candidate for SMA, an orphan disease, plays an important role in demonstrating new applications of our technology platform based on tetracycline derivatives and in the extension of Paratek's R&D pipeline into genetic disorders."

Paratek reported early preclinical research from the collaboration at the recent annual meeting of the American Academy of Neurology. In vitro data showed that tetracycline derivatives could modify defective splicing of mRNA resulting from the gene defect seen in SMA. More research, including in vivo preclinical studies, is planned and will be presented in the suitable peer-reviewed forum in the future.

About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases, with a particular focus on the growing worldwide problem of antibiotic resistance. Paratek is advancing novel compounds that can circumvent or block bacterial resistance. Paratek's lead compound, PTK 0796, is a broad spectrum antibiotic derived from the tetracycline class with oral and IV formulations that is being developed for the treatment of the most common and serious hospital bacterial infections, including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae). Oral and IV formulations of PTK 0796 were compared to Zyvox(R) in a recently completed Phase 2 clinical study in complicated skin and skin structure infections (cSSSI). In addition to PTK 0796, Paratek is also developing other broad- and narrow-spectrum tetracycline antibiotics to treat hospital and community infections based on its novel tetracycline chemistry expertise.
Outside of its tetracycline antibacterial program, Paratek has also identified small molecules that inhibit bacteria-specific transcription factors for Multiple Adaptational Response (MAR) genes which control bacterial virulence and resistance development.

Based upon a growing body of clinical research and as part of its effort to exploit its novel tetracycline derivatives and their unique mechanism of action in selected inflammatory and neurodegenerative conditions, Paratek has an active chemical synthesis effort to produce novel and diverse small molecules, with the goal of developing non-antibacterial compounds with improved activity in serious inflammatory and neurodegenerative diseases. In addition, Paratek is encouraged by early evidence of the ability of
tetracycline derivatives to affect mRNA splicing, as in SMA, which may also have activity in related orphan genetic disorders, such as cystic fibrosis (CF), and Duchene Muscular Dystrophy.

Paratek has active collaborations with Merck & Co., MerckSerono, Warner-Chilcott and FSMA to develop tetracycline derived small molecule drugs for bacterial infections, multiple sclerosis (MS), acne & rosacea, and spinal muscular atrophy (SMA), respectively. Paratek is privately held and headquartered in Boston, Massachusetts, USA. For more information about Paratek and its research and development initiatives, visit Paratek's website at http://www.paratekpharm.com

רשק רוצ

העדוה ספדה הכנת ההודעה להדפסה

רבחל חלש

הבוגת

:תויורשפא

(20:28 19/06/08) ןהכ ירימ תירבעל SMA רמאמ םוגרתב הרזע

,םולש
תלחמב רושקה ל"נה רמאמה תא םגרתל ונל רוזעל לכוי והשימ םאה
.דואמ ול הדונ SMA
ירימ הדות
Drug Discovery Collaboration for Spinal Muscular Atrophy
Atrophy and Paratek Pharmaceuticals Extend and Expand
Families of Spinal Muscular

derived from the tetracycline class of compounds.
the clinic a novel small molecule within Paratek's library
collaboration is focused on optimizing and advancing into
of death of children under the age of two years. The
Atrophy (SMA), the leading genetically inherited cause
a drug candidate for the treatment of Spinal Muscular
joint research and development collaboration to develop
they have extended and significantly expanded their
(FSMA) and Paratek Pharmaceuticals, Inc. today announced
June 17 /PRNewswire/-- Families of Spinal Muscular Atrophy
LIBERTYVILLE, Ill., and BOSTON,

and Science are also key collaborators in the program.
Laboratory at Rosalind Franklin University of Medicine
at Cold Spring Harbor Laboratory and the Hastings
their investment in the effort. The Krainer Laboratory
dedicated to the program, with both partners increasing
for a third year and to approximately triple the resources
The partners have agreed to extend their collaboration

to the control of muscles in the limbs, neck and chest.
functioning of the motor neurons in the spinal cord and
of the SMN protein, which is essential to the proper
gene. This causes a chronic deficiency in the production
loss of both copies of the Survival Motor Neuron (SMN1)
is an often-fatal genetic disorder resulting from the
Spinal Muscular Atrophy

to transition from non-profit to commercial sources."
progress to later stages, we are looking for funding
for this orphan disease. As this and other programs
funds to enable companies to begin early-stage programs
at FSMA. "Our drug discovery strategy is to invest
of commitment," said Kenneth Hobby, Executive Director
of this collaborative program justify this new level
"We are excited that the early, positive results

awareness about SMA to the Boston biotech community."
in the U.S. During our conference, we hope to increase
this year -- an important hub of the biotech industry
"FSMA is excited to be in Boston for our conference
Awareness Day" for the City of Boston. Mr. Hobby stated,
M. Menino has proclaimed Saturday, June 21st as "SMA
and a cure for this devastating disease. Mayor Thomas
researchers and companies working to discover treatments
in the world for families affected by SMA and also for the
Paratek is headquartered. This is the largest conference
community bringing its annual conference to Boston, where
This exciting announcement also coincides with the SMA

in a number of tissues in animal models of the disease."
generated by Paratek have been shown to accomplish this
by correcting the splicing of the SMN2 gene. Compounds
restores the proper amount of SMN protein in the body
is to develop an SMA drug that safely and effectively
FSMA's Research Director added, "The goal of this effort
Jill Jarecki, Ph.D.,

of Paratek's R&D pipeline into genetic disorders."
based on tetracycline derivatives and in the extension
demonstrating new applications of our technology platform
for SMA, an orphan disease, plays an important role in
of our SMA program. Developing a clinical candidate
with FSMA and equally excited about the progress
with the continuation and expansion of our collaboration
Officer and co-founder, stated, "We are extremely pleased
B. Levy, M.D., Paratek's Vice Chairman, Chief Scientific
Dr. Stuart

in the suitable peer-reviewed forum in the future.
vivo preclinical studies, is planned and will be presented
the gene defect seen in SMA. More research, including in
could modify defective splicing of mRNA resulting from
In vitro data showed that tetracycline derivatives
annual meeting of the American Academy of Neurology.
preclinical research from the collaboration at the recent
Paratek reported early

About Paratek Pharmaceuticals, Inc.
based on its novel tetracycline chemistry expertise.
antibiotics to treat hospital and community infections
developing other broad- and narrow-spectrum tetracycline
(cSSSI). In addition to PTK 0796, Paratek is also
study in complicated skin and skin structure infections
to Zyvox(R) in a recently completed Phase 2 clinical
Oral and IV formulations of PTK 0796 were compared
and MDRSP (multi-drug resistant Streptococcus pneumoniae).
such as MRSA (methicillin-resistant Staphylococcus aureus)
infections, including those caused by resistant strains
of the most common and serious hospital bacterial
IV formulations that is being developed for the treatment
derived from the tetracycline class with oral and
lead compound, PTK 0796, is a broad spectrum antibiotic
can circumvent or block bacterial resistance. Paratek's
resistance. Paratek is advancing novel compounds that
focus on the growing worldwide problem of antibiotic
serious and life-threatening diseases, with a particular
and commercialization of new therapeutics that treat
Paratek Pharmaceuticals, Inc. is engaged in the discovery
control bacterial virulence and resistance development.
for Multiple Adaptational Response (MAR) genes which
that inhibit bacteria-specific transcription factors
program, Paratek has also identified small molecules
Outside of its tetracycline antibacterial

Paratek is encouraged by early evidence of the ability of
inflammatory and neurodegenerative diseases. In addition,
compounds with improved activity in serious
molecules, with the goal of developing non-antibacterial
synthesis effort to produce novel and diverse small
conditions, Paratek has an active chemical
of action in selected inflammatory and neurodegenerative
novel tetracycline derivatives and their unique mechanism
clinical research and as part of its effort to exploit its
Based upon a growing body of
as cystic fibrosis (CF), and Duchene Muscular Dystrophy.
have activity in related orphan genetic disorders, such
to affect mRNA splicing, as in SMA, which may also
tetracycline derivatives

visit Paratek's website at http://www.paratekpharm.com
Paratek and its research and development initiatives,
in Boston, Massachusetts, USA. For more information about
respectively. Paratek is privately held and headquartered
(MS), acne & rosacea, and spinal muscular atrophy (SMA),
drugs for bacterial infections, multiple sclerosis
and FSMA to develop tetracycline derived small molecule
with Merck & Co., MerckSerono, Warner-Chilcott
Paratek has active collaborations

רשק רוצ

העדוה ספדה הכנת ההודעה להדפסה

רבחל חלש

הבוגת

:תויורשפא

(14:22 11/06/08) לג דוד עוצמל רוזעל לוכי והשמ םא גוז תב שפחמ 23ןב ןשוד הלוח ינא םולש

(09:58 08/06/08) אנהכ לכימ תוינווינ םירירש תולחמ

(14:44 09/06/08) קחציו הליא םירירש ןווינ תולחמל ימרוג

(10:13 31/05/08) הרמכ השנמ ס"יב רויסב הכנ הדלי בוליש

(15:55 19/05/08) קחציו הליא יוניש םירצוי םידחוימ םיכרצ םע םידליל םירוה - סנכ

יוניש םירצוי םידחוימ םיכרצ םע םידליל םירוה ;#8211& סנכ
2008 ינוי ;#8211&

,ךוניחהו החוורה ידרשמ ףותישב ,םיס"נתמל הרבחהו 'רשק' ,םילשא
םע םידליל תוחפשמ לש םוחתב תונוש םיכרדב םיקסועה םינוגראו
:אשונב סנכ םיכרוע ,םידחוימ םיכרצ

יוניש םירצוי םידחוימ םיכרצ םע םידליל םירוה

םיסנכה זכרמב 26.6.08 ח"סשת ןויס 'גכ ישימח םויב םייקתי סנכה
10 המוק ,לוגע ןיינב ,ביבא לת ,132 ןיגב םחנמ ךרד ,ילאירזע

עוצקמ ישנאו םידחוימ םיכרצ םע םידליל םירוהל דעוימ סנכה
.םוחתב

הלש תוחוכה .החפשמה לש החוכ לע םירוהה םע דחיב דומלל הרטמה
תוחוכהו ,םייח תוכיאל םיכרד אוצמל ךיא ;#8211& התיבל המינפ
;#8211& הרבחה ינפ יונישל ,תונגראתהו הריבח ךות ,הצוחה הלש
.םינוש םיאשונ םודיקבו םיתוריש חותיפב ,הקיקחב

:תינכתב

עדימה דיריב רויסו םושיר ,תוסנכתה 08.30-09.30

םוחתב םיקסועה תויונגראתהו םינוגרא לש

תוכרב 09.30-10.00

ךוניחה תרש ,רימת ילוי 'פורפ כ"ח

םיתורישהו החוורה רש ,גוצרה קחצי כ"ח
םייתרבחה

תינגס ,'רשק' ר"וי ,ילאירזע הנד 'בגה
תצובק אישנ

ילאירזע

,םילשא ל"כנמ ,ינמילוס ימר ר"ד
לארשי טניו'ג

םיס"נתמל הרבחה ל"כנמ ,רלג ריאי רמ

יאמ ירימ ;#8211& הריש עטק

היווה ןיב עסמ ;#8211& "דחוימ דליל הרוה תויהל" 10.00-10.30
תישיא

תיתרבח היישעל

ילע ר"וי ,גומלא ןורוד םיאולימב ףולא
ןרע תלחנ ;#8211& בגנ

תורוה לע שדח טבמ ;#8211& "ןקתפרהל ןברוקמ" 10.30-11.00

םידחוימ םיכרצ םע םידליל

תולוכי חותיפל הרומ ,ירומ לט 'בגה
תוישיא

היצזיבורפמיא ןורטאית ;#8211& "וניניבש המ" 10.00-11.20

לע - "ונתיא טלחוי ;#8211& ונב רושקה לכ" 11.20-11.50
,תומזי

תוברעתהו תוברועמ

ן"ילא ל"כנמ ,םייח רב יקיא רמ
םעונ תיב ;#8211&

עדימה דיריב רויס ךשמהו הקספה 11.50-12.20

םיכרצמ םע יוניש םילשבמ דסממו םירוה" 12.20-12.50

תויוכז ,עדי ,עדימ ;#8211& "םידחוימ
...תוקרי ראשו

ףגא ,תיצרא תחקפמ ,םייהדרוג ילש ר"ד
,םוקישה

םייתרבחה םיתורישהו החוורה דרשמ

ןוגרא תיל"כנמ ,ןיפשירק ימת 'בגה
'רשק'

היצזיבורפמיא ןורטאית ;#8211& "וניניבש המ" 12.50-13.10

הרוהה דיקפת לע ;#8211& "ינא אוה הזה דליהו" 13.10-13.40
תדוקנמ

הכנה דליה לש וטבמ

םיכנה קבאמ הטמב ליעפ ,םירק באוי רמ

םוכיס ירבד 13.40-14.00

םיכנל הקלחמה להנמ ,לכייר ןונמא רמ
תויסולכואו

םיס"נתמל הרבחה ,תודחוימ

םיירהצ תחורא 13.40-14.00

לוק לש 'ב תשרב תויתרבח תוינכת שיגמו ךרוע ,ורימ יקימ :החנמ
לארשי

ידרשמב םשריהל אנ לבגומ תומוקמה רפסמו רחאמ ,תישפוח הסינכה
השגנה יכרוצ ןייצל אנ ,<יוסח רפסמ> 'לט ,םיס"נתמל הרבחה

םילזומ היינח יסיטרכ שוכרל ןתינ סנכל המשרהה תדמעב

ילאירזע תצובק תוסחב סנכה

רשק רוצ

העדוה ספדה הכנת ההודעה להדפסה

רבחל חלש

הבוגת

:תויורשפא

(15:57 19/05/08) קחציו הליא יוניש םירצוי םידחוימ םיכרצ םע םידליל םירוה -סנכ

(12:42 18/05/08) קחציו הליא "הצע" תתומעב תויומלתשה

(23:18 17/05/08) הרמכ השנמ "דסחה תוא" סרפ

(11:55 18/05/08) קחציו הליא דסחה תוא ןתמל הצלמה ספוט

(00:32 09/05/08) הרמכ השנמ [ת"ל] 2/7/07 ב םסרופ-באוכה באה

(08:14 16/12/07) קחציו הליא םירקוחו םיאפור ןשוד ילוחל ףסונ זכרמ רתא

(23:55 08/05/08) הרמכ השנמ ןשודב םיינילק םייוסינל הטוי תטיסרבינוא לש רתאה תבותכ

(08:21 17/03/08) קחציו הליא םידיג רוציק תעינמל םילופטו בגה בוציל םיחותינ

(09:52 08/05/08) .ל ןסינ רזע אל םידיגל חותינש קיתו הרוה לש ןויסנמ

(09:55 08/05/08) .ל ןסינ םידסב שומישו היפרתויזיפה תובישח

(16:45 02/03/08) חתי םייח ןשוד הלוחל תמקע חותינ

(09:47 08/05/08) .ל ןסינ תפרצב ףידעש הארנכ

(09:44 08/05/08) .ל ןסינ ?ליעיו חונ שומישל םיפיט - ןוטסוב ךוחמ

(14:23 18/04/08) ב יגח י.ש.מ תתומעל תופרטצה

(13:12 21/04/08) קחציו הליא התומעל תופרטצה

(19:19 22/04/08) כ ןדיע יגח םולש

מ"עב קטביטקא ידי-לע המקוה וז ןויד תצובק

"םירוביד" -ב םניח םורופ חתפ